1439126
Last Update Posted: 2014-10-27
Recruiting has ended
All Genders accepted | 6 Years-17 Years |
135 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Efficacy & Safety of KAPVAY™ Extended-Release in Children & Adolescents With Attention Deficit Hyperactivity Disorder
The purpose of this study is to determine the long-term efficacy and safety of KAPVAY™ (clonidine hydrochloride) extended-release in children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
Eligibility
Relevant conditions:
Attention Deficit Hyperactivity Disorder
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
Inclusion criteria
Exclusion criteria
locations
Data sourced from ClinicalTrials.gov